Company profile: Soligenix
1.1 - Company Overview
Company description
- Provider of vaccines and therapeutics for biodefense and rare diseases, including HyBryte photodynamic therapy for cutaneous T-cell lymphoma; SGX302 light therapy for psoriasis; SGX942 IV dusquetide for severe oral mucositis in cancer patients; RiVax in-development ricin vaccine using ThermoVax thermal stabilization; and SGX943 dusquetide to reduce inflammation, eliminate infection, and enhance tissue healing in infectious diseases.
Products and services
- HyBryte: A visible-light-activated photodynamic therapy employing synthetic hypericin for treating Cutaneous T-Cell Lymphoma
- Illumination triggers hypericin activation as part of the therapeutic procedure
- ThermoVax: A proprietary thermal stabilization method for vaccines that allows them to remain potent at elevated temperatures, preserving effectiveness when exposed to heat
- RiVax: An in-development vaccine for the prevention of ricin poisoning that utilizes Soligenix’s proprietary thermal stabilization technology
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Soligenix
Civitas Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies focused on pulmonary drug delivery for central nervous system and respiratory disorders. Offers INBRIJA (levodopa inhalation powder) for Parkinson’s symptoms, the ARCUS technology platform for pulmonary delivery of medications enhancing drug delivery efficiency, and AMPYRA (dalfampridine) to improve walking in multiple sclerosis. Serves patients throughout the United States.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Civitas Therapeutics company profile →
Primrose Therapeutics
HQ: United States
Website
- Description: Provider of biotechnology research and development focused on creating treatments for polycystic kidney disease (PKD), a life-threatening genetic disorder affecting 600,000 Americans and 12.5 million people worldwide.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Primrose Therapeutics company profile →
Vtesse Pharma
HQ: United States
Website
- Description: Provider of rare disease drug development for underserved patients, working collaboratively to advance VTS-270, which has shown promise in pre-clinical and clinical studies as a potential treatment for Niemann-Pick Disease; first spin-out of Cydan Development, Inc., an orphan-drug accelerator.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vtesse Pharma company profile →
Ultragenyx
HQ: United States
Website
- Description: Provider of therapeutics for rare and ultra-rare diseases, including CRYSVITA for XLH, MEPSEVII for MPS VII, and DOJOLVI for LC-FAOD. Develops investigational therapies such as UX143 (setrusumab) for osteogenesis imperfecta and GTX-102 for Angelman syndrome. Offers UltraCare patient support with assistance for insurance coverage, financial support, and access to resources.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ultragenyx company profile →
True North Therapeutics
HQ: United States
Website
- Description: Provider of biotechnology therapeutics that selectively inhibit the Complement pathway for diseases of high unmet clinical need, featuring lead monoclonal antibody TNT009 targeting the Classical Complement pathway to selectively inhibit downstream phagocytosis, inflammation, and cell lysis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full True North Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Soligenix
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Soligenix
2.2 - Growth funds investing in similar companies to Soligenix
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Soligenix
4.2 - Public trading comparable groups for Soligenix
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →